Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting
b'CAMBRIDGE, Mass., SUZHOU, China andROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company,presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting.
- b'CAMBRIDGE, Mass., SUZHOU, China andROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company,presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting.
- This meeting is being held virtually from April 10-15, 2021.
- The anti-B7H7 antibody is a novel immune-oncology antibody with potent anti-tumor activity generated using HBM\'s proprietary H2L2 Harbour Mice platform.\nBy leveraging its innovative discovery engine based on the Harbour Mice antibody platforms, HBM has built a sustained capability to deliver novel antibody therapeutics in the field of oncology and immunology.
- Following the previously reported monoclonal antibody against a novel target CCR8, HBM now reports another first-in-class therapeutic antibody targeting a novel immune checkpoint - B7H7.